For comments, suggestions
Created with Raphaël 2.1.0 19.08.2016 Filing date 27.03.2018 Validation fee payment 31.08.2018 (A1) Patent application published 23.12.2022 AGEPI application filing date 30.04.2023 (T2) Translation of the validated European patent 08.05.2025 19.08.2025 Valid until 20.08.2026 Renewal fee to be paid until 19.08.2036 Patent will expire on

Patent in force


(210)Number of the EPO application16771021
(220)Filing date of the EPO application2016.08.19
(80)EPO patent specification publication (B)EPB nr. 41/2022, 2022.10.12
(110)EPO patent number3340966
(11)Number of the documentMD 3340966 T2
(21)Number of the applicatione 2018 0654
(71)Name(s) of applicant(s), code of the countryELI LILLY AND COMPANY, US;
(72)Name(s) of inventor(s), code of the countryAKERS Michael Patrick, US;
CHRISTE Michael Edward, US;
HARDY Thomas Andrew, US;
MAJUMDAR Ranajoy, US;
NGUYEN Chi A., US;
PAAVOLA Chad D., US;
SARIN Virender Kumar, US;
SCHULTE Nanette Elizabeth, US;
(73)Name(s) of owner(s), code of the countryELI LILLY AND COMPANY, US;
(54)Title of the inventionRapid-acting insulin compositions
(13)Kind-of-document code T2
(51)International Patent Classification A61K 9/00 (2006.01.01); A61K 38/28 (2006.01.01); A61K 47/02 (2006.01.01); A61K 47/12 (2006.01.01); A61K 47/10 (2017.01.01); A61K 31/192 (2006.01.01); A61P 3/10 (2006.01.01); A61K 47/34 (2017.01.01)
(19)CountryUS
(41)Date of publication of the application2018.08.31
(49)Date of publication of the translation of the validated European patent specification2023.04.30
(30)Priority201562210469 P, 2015.08.27, US
(74)Patent attorney(Procedură) PARASCA Dumitru, str. Eminescu nr. 40, ap. 13, c/p 28, MD-2012, Chişinău, Republica Moldova
(86)International applicationPCT/US2016/047723, 2016.08.19
(87)International publicationWO 2017/034956, 2017.03.02
Up
/Inventions/details/3340966